Pediatric Induction Therapy in Kidney Transplantation

Induction Therapy of Thymoglobulin Versus Basiliximab in the Prevention of Acute Rejection After Pediatric Kidney Transplantation

The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children. The main question it aims to answer is:

Is basiliximab (anti-CD25 monoclonal antibody) induction therapy effective and safe in preventing AR after kidney transplantation in children compared with anti-thymoglobulin polyclonal antibodies induction therapy?

The transplant and follow-up data of participants will be retrospectively collected.

Researchers will compare the rate of AR to see if basiliximab (anti-CD25 monoclonal antibody) induction therapy is a better option for certain pediatric kidney transplant recipients.

Inclusion Criteria:

• Receiving the kidney graft from a deceased donor
• Basiliximab or rATG induction therapy was used in perioperative period

Exclusion Criteria:

• Recipients with pre-transplant calculated panel reactive antibodies (cPRA) >10%
• Recipients of combined liver, pancreas or heart transplantation
• No induction or other induction therapy was used in perioperative period
• Recieving the kidney graft from a living donor